Redox State of Human Serum Albumin and Inflammatory Biomarkers in Hemodialysis Patients with Secondary Hyperparathyroidism During Oral Calcitriol Supplementation for Vitamin D
Authors:
Open Access
- 18 October 2018
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Medicinal Chemistry Journal
- Vol. 12 (1) , 98-110
Abstract
Hemodialysis (HD) patients with secondary Hyperparathyroidism (s-HPT) are exposed to increased inflammation and oxidative stress. In HD patients, oxidized albumin is a reliable marker of oxidative stress and its clinical significance has been rarely studied. The objective of this study was to evaluate Cys34 Human Serum Albumin (HSA) as oxidative stress biomarker in HD patients with s-HPT and its relationship with inflammation on bone turnover markers during oral calcitriol supplementation for vitamin D. Fifteen stable hemodialysis patients with s-HPT (mean age 48.67±8.15, 11 males and 4 females) were used in the experiment to receive calcitriol treatment for 16 weeks (0.25mcg or 0.5 mcg once a day according to serum level of Ca and P for each). The changes in the serum biochemical parameters (Ca, P, ALP, and iPTH), inflammatory markers (CRP and IL-6 levels) and serum oxidative stress condition (SOD, IS and albumin ratio HNA/HMA) were evaluated before and at 8 and 16 weeks of calcitriol treatment. The correlations between those factors were studied. All patients responded to oral calcitriol therapy, with a significant decrease in the serum iPTH. The results showed that calcitriol could effectively suppress iPTH secretion with a significant elevation of serum Ca and P but ALP remained unchanged during the study. It can also effectively reduce the inflammatory markers (CRP and IL-6), while increasing the oxidative markers (SOD and IS). Oxidative albumin ratio HNA/HMA showed a significant (p=0.001) reduction after 16 weeks of calcitriol treatment and the redox state of HSA showed a positive prediction for hyperparathyroidism and for inflammation. The redox state of HSA could be used as a predictor for monitoring hyperparathyroidism and inflammation during calcitriol treatment by retarding albumin oxidation in HD patients with secondary hyperparathyroidism.Keywords
This publication has 40 references indexed in Scilit:
- Paricalcitol reduces oxidative stress and inflammation in hemodialysis patientsBMC Nephrology, 2012
- Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markersNephrology Dialysis Transplantation, 2008
- Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney DiseaseHypertension, 2008
- Vitamin D levels and early mortality among incident hemodialysis patientsKidney International, 2007
- The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burstBiochemical and Biophysical Research Communications, 2005
- Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome2004
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Intravenous iron administration induces oxidation of serum albumin in hemodialysis patientsKidney International, 2004
- Albumin is the major plasma protein target of oxidant stress in uremiaKidney International, 2001
- Importance of oxidatively modified proteins in chronic renal failureKidney International, 2001